We have designed a dual-aptamer complex specific to both prostate-specific membrane antigens (PSMA) (+) and (–) prostate cancer cells. In the complex, an A10 RNA aptamer targeting PSMA (+) cells ¬¬and a DUP-1 peptide aptamer specific to PSMA (–) cells were conjugated through streptavidin. Doxorubicin loaded onto the stem region of the A10 aptamer was delivered not only to PSMA (+) cells but to PSMA (–) cells, and eventually induced apoptosis in both types of prostate cancer cells. Furthermore, both aptamers were immobilized onto the TCL-SPION for the in vivo application of the dual-aptamer-based drug delivery system. Doxorubicin was selectively passed into both types of prostate cancer cells due to the specificity of the dual-aptamer probe. This indicates that targeted drug delivery to prostate cancer cells successfully occurred using the drug-loaded aptamer complex via streptavidin and the probe using nanoparticles. In particular, dual-aptamer nanoparticles can be applied as an active drug delivery vector in vivo for the general targeting of both types of prostate cancer, including the PSMA (–) cell line, due to the particles’ suitability for use as MR contrast agents.
Journal: TechConnect Briefs
Volume: 3, Nanotechnology 2013: Bio Sensors, Instruments, Medical, Environment and Energy (Volume 3)
Published: May 12, 2013
Pages: 131 - 134
Industry sector: Medical & Biotech
Topics: Diagnostics & Bioimaging, Sensors - Chemical, Physical & Bio